CORCEPT THERAPEUTICS INC (CORT)

US2183521028 - Common Stock

22.935  +0.22 (+0.99%)

News Image
5 days ago - Seeking Alpha

Corcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

News Image
5 days ago - Corcept Therapeutics Incorporated

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image
5 days ago - Corcept Therapeutics Incorporated

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image
6 days ago - Chartmill

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.

News Image
12 days ago - Corcept Therapeutics Incorporated

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and...

News Image
22 days ago - Corcept Therapeutics Incorporated

Corcept Appoints Roberto Vieira as President, Oncology

News Image
a month ago - Seeking Alpha

Corcept Therapeutics reports prelim Q4 rev above estimate (NASDAQ:CORT)

Corcept Therapeutics reports strong Q4 revenue, beating estimates and providing positive 2024 revenue guidance.

News Image
2 months ago - Seeking Alpha

Canaccord Genuity sees Corcept sell-off as buying opportunity (NASDAQ:CORT)

Canaccord Genuity said Tuesday that it regards the sell-off in Corcept Therapeutics (CORT) shares as a buying opportunity, given that the company intends to app

News Image
2 months ago - Corcept Therapeutics Incorporated

Court Finds Corcept Therapeutics’ Patents Not Infringed

News Image
2 months ago - Seeking Alpha

Corcept Therapeutics stock plunges after loss in patent battle with with Teva

Corcept Therapeutics (CORT) tumbles 38% in after-hours trading following a patent trial loss to Teva (TEVA) over its Cushing's syndrome drug, Korlym.

News Image
3 months ago - InvestorPlace

7 Underappreciated Biotech Stocks to Pick Up on the Cheap

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

News Image
4 months ago - Market News Video

Corcept Therapeutics is Now Oversold (CORT)